Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZBIO Zenas BioPharma Inc.

Market Closed 04-10 16:00:00 EDT

20.44

-0.84

-3.95%

盘后20.44

+0.000.00%

18:29 EDT

High21.65	Low20.13	Vol384.73K
Open21.28	D1 Closing21.28	Amplitude7.12%
Mkt Cap1.27B	Tradable Cap814.36M	Total Shares62.37M
T/O7.87M	T/O Rate0.97%	Tradable Shares39.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":20.44,"timestamp":1775851200000,"preClose":21.28,"halted":0,"volume":384727,"hourTrading":{"tag":"盘后","latestPrice":20.44,"preClose":20.44,"latestTime":"18:29 EDT","volume":3728,"amount":76204.35,"timestamp":1775860150345,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03947368421052631,"floatShares":39841600,"shares":62371044,"eps":-8.44,"marketStatus":"Market Closed","change":-0.84,"latestTime":"04-10 16:00:00 EDT","open":21.28,"high":21.645,"low":20.13,"amount":7867784.9485,"amplitude":0.071194,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.44,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":21.28,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":20.44,"preClose":20.44,"latestTime":"18:29 EDT","volume":3728,"amount":76204.35,"timestamp":1775860150345,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4565188810440298,"impliedVol":1.5757,"impliedVolPercentile":0.9724},"requestUrl":"/m/hq/s/ZBIO/wiki","defaultTab":"wiki","newsList":[{"id":"2625497289","title":"Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625497289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625497289?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:36","pubTimestamp":1775651788,"startTime":"0","endTime":"0","summary":"In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Zenas BioPharma, Inc., with a price target of $21.00. Fro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-reaffirms-their-hold-rating-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-reaffirms-their-hold-rating-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","LU0795875086.SGD","LU1244550494.USD","BK4127","LU1668664300.SGD","BK4504","BK4516","BK4581","LU2028103732.USD","LU0882574139.USD","LU2347655156.SGD","LU0006306889.USD","LU1074936037.SGD","LU0106831901.USD","LU0320765646.SGD","LU0971096721.USD","LU1732800096.USD","LU2023251221.USD","LU0557290698.USD","LU0528227936.USD","LU2089283258.USD","BK4585","LU1548497426.USD","LU1720051017.SGD","LU0912757837.SGD","BK4139","LU1244550577.SGD","LU1720051108.HKD","LU2357305700.SGD","LU2271345857.HKD","LU0158827948.USD","LU1244550221.USD","LU0795875169.SGD","LU2111349929.HKD","LU1732799900.SGD","LU2089284900.SGD","LU2133065610.SGD","LU0158827781.USD","LU0225283273.USD","LU1791710400.SGD","LU0314104364.USD","ZBIO","LU1363072403.SGD","LU1989772840.SGD","BK4588","LU1162221912.USD","LU0098860793.USD","IE00BZ1G4Q59.USD","LU1989772923.USD","LU1791710582.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624687110","title":"Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624687110","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624687110?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:03","pubTimestamp":1775163781,"startTime":"0","endTime":"0","summary":"Zenas BioPharma director Hongbo Lu reported an indirect purchase of 3,768 common shares at USD 18.63 each.Indirect beneficial ownership rose to 426,736 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1ckfL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624529152","title":"Major Insider Move Signals Growing Confidence in Zenas BioPharma’s Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2624529152","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624529152?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:05","pubTimestamp":1775095557,"startTime":"0","endTime":"0","summary":"New insider activity at Zenas BioPharma, Inc. ( ($ZBIO) ) has taken place on April 1, 2026. Director Fairmount Funds Management LLC has significant...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-zenas-biopharmas-future-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-zenas-biopharmas-future-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624541688","title":"Fairmount Healthcare Fund II acquires Zenas BioPharma shares worth $3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624541688","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624541688?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:32","pubTimestamp":1775075523,"startTime":"0","endTime":"0","summary":"Fairmount Healthcare Fund II bought 150,000 Zenas BioPharma common shares at USD 20 per share.Tomas Kiselak, managing member at Fairmount Funds Management, is listed as director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL226cV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fairmount Healthcare Fund II acquires Zenas BioPharma shares worth $3 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624552550","title":"Zenas BioPharma Raises Capital via Notes and Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2624552550","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624552550?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:20","pubTimestamp":1775002851,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. ( ($ZBIO) ) has issued an update. On March 31, 2026, Zenas BioPharma completed a $200 million public offering of 2.50% Conver...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-raises-capital-via-notes-and-equity-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-raises-capital-via-notes-and-equity-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","ZBIO","BK4585","BK4588","BK4139","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624554405","title":"Zenas BioPharma director buys $1.5M in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2624554405","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624554405?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:45","pubTimestamp":1775000716,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Zenas BioPharma (ZBIO) disclosed that its director Hongbo Lu bought 75K shares of common stock on March 31 in a total trans...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-director-buys-1-5m-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-director-buys-1-5m-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624553869","title":"Zenas BioPharma director Hongbo Lu reports $1.5 million common share acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2624553869","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624553869?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:03","pubTimestamp":1774990981,"startTime":"0","endTime":"0","summary":"Zenas BioPharma director Hongbo Lu reported an indirect purchase of 75,000 common shares at USD 20 per share.Indirect beneficial ownership rose to 422,968 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL8VtnVj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas BioPharma director Hongbo Lu reports $1.5 million common share acquisition","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622872116","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2622872116","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622872116?lang=en_us&edition=fundamental","pubTime":"2026-03-28 02:28","pubTimestamp":1774636086,"startTime":"0","endTime":"0","summary":"Burford Capital , which backed and funded litigation against Argentina over its nationalization of YPF, tumbled 41% after a US appeals court reversed a ruling ordering the country to pay $16.1 billion to former shareholders of the oil company, according to media reports.Intraday trading volume surged to over 28.2 million shares from a daily average of about 1.85 million.Zenas BioPharma  priced a $200 million offering of 2.50% convertible senior notes due 2032 and a separate equity offering of 5 million shares at $20 per share.Shares dropped 18%, with more than 1.95 million shares traded intraday versus a daily average of roughly 894,000.Norwegian Cruise Line  said Friday it has entered into a cooperation agreement with activist investor Elliott Investment Management and has appointed new members to its board.Shares dropped 7%, with intraday trading volume of over 14.4 million, versus a daily average of about 21.3 million.Price: 4.52, Change: -3.32, Percent Change: -42.34","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4517","BUR.AU","BK4139","NCLH","BK4585","BK4588","BUR","BK4142","ZBIO","BK4164","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622499876","title":"Zenas BioPharma Tumble on Pricing of Convertible-Note, Stock Public Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622499876","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622499876?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:03","pubTimestamp":1774627380,"startTime":"0","endTime":"0","summary":"Shares of Zenas BioPharma continued to slide after the company said it would raise $200 million through a convertible senior note sale and sell 5 million shares at $20 a share in a public offering.The stock fell 19%, to $18.01, midday Friday, but has more than doubled in value over the past year.The company said Friday that it expects to net about $287.5 million collectively from the two transactions, which would support its development pipeline and the planned commercial launch of obexelimab to treat the inflammatory condition IgG4-RD, if approved.Zenas announced the transactions after the market closed on Thursday. Shares slipped 9.8% in after-hours trading following the announcement.The company said the underwriters of the public offering have a 30-day option to buy up to 750,000 shares at the same price.It is selling unsecured, senior notes with a 2.5% interest rate and a maturity date of April 1, 2032.Jefferies, Evercore ISI, Citigroup, and Guggenheim Securities are acting as join","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Zenas BioPharma Tumble on Pricing of Convertible-Note, Stock Public Offerings","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622876306","title":"BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2622876306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622876306?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:48","pubTimestamp":1774626488,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL6N40F0XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","FIAT","FPS","BTGO","ZBIO","CONI","FCHL","WIX","RCKT","CCL","ANAB","PWR","VOR","SHPH","LTRN","PANW","GGLS","SST","AME","DTCX","IEX","ITRM","EMR","HKIT","GGLL","HON","CONX","DIS","DOV","ITRMF","CRWD","AGX","SAIL","02026","TWO","ICOI","ADMA","CCL.UK","DISO","VATE","FTNT","ARTL","DDOG","PH","ETR","BKSY","ETN"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622814573","title":"Zenas Biopharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock With Aggregate Gross Proceeds of $300.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622814573?lang=en_us&edition=fundamental","pubTime":"2026-03-27 12:12","pubTimestamp":1774584751,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nTUA21QHZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622689200","title":"Stocks to Watch: Datacentrex, Unity Software, Veritone, Zenas BioPharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689200?lang=en_us&edition=fundamental","pubTime":"2026-03-27 07:10","pubTimestamp":1774566600,"startTime":"0","endTime":"0","summary":"Datacentrex commenced a public offering of shares. The stock slid 26%, to $2.30, in after-hours trading Thursday.Unity Software posted a higher-than-expected sales outlook and said it plans to exit and divest from certain businesses. Shares rose 13%, to $19.40, after the bell.Veritone swung to a loss in the fourth quarter. The stock declined 7.3%, to $2.42.Zenas BioPharma commenced a public offering to fund the launch of one of its drug products in the U.S. Shares fell 10%, to $20.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861558580.USD","BK4023","BK4585","UNX","DTCX","U","BK4543","VERI","BK4579","LU1861559042.SGD","ZBIO","BK4554","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622689145","title":"BUZZ-Zenas BioPharma drops on convertible, equity offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689145","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689145?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:15","pubTimestamp":1774559710,"startTime":"0","endTime":"0","summary":"BUZZ-Zenas BioPharma drops on convertible, equity offerings** Zenas BioPharma ZBIO.O shares down 9.8% post-market to $20 after capital raise news ** Autoimmune disease specialist commences public offerings of 6-yr convertible bonds and common stock without disclosing deal sizes** Says intends to use net proceeds from both offerings, which are not conditioned upon each other, to support planned U.S. commercial launch of obexelimab, if approved, and advance its development pipeline** Jefferies, Evercore, Citigroup and Guggenheim Secs joint bookrunners** On Jan 5, ZBIO shares plunged 52% after obexelimab cut the risk of flare-ups in patients with immunoglobulin G4-related disease, but showed weaker-than-expected efficacy in a late-stage study** ZBIO stock closed down 0.1% at $22.16 on Thurs. Stock off 39% YTD after surging more than four-fold in 2025** Waltham, Massachusetts-based co has ~57.4 mln shares outstanding for ~$1.3 bln market cap** Avg rating of 8 analysts is \"strong buy\"; medi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL6N40E1B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0980610538.SGD","LU1162221912.USD","LU2456880835.USD","LU1506573853.SGD","BK4559","BK4585","BK4139","LU2417539215.USD","LU0130517989.USD","LU2125154935.USD","LU2360032135.SGD","LU0314106906.USD","LU0477156953.USD","LU2462157665.USD","BK4534","EVR","LU2125154778.USD","LU1244550494.USD","BK4207","LU0162691827.USD","LU0052756011.USD","LU0170899867.USD","LU1791807156.HKD","LU0128525689.USD","LU0098860793.USD","BK4588","BK4566","BK4127","LU0648001328.SGD","LU1668664300.SGD","IE00BSNM7G36.USD","LU0130102774.USD","ZBIO","LU0310800965.SGD","LU1267930227.SGD","LU2236285917.USD","LU0320765646.SGD","LU1244550577.SGD","LU0072461881.USD","LU1201861249.SGD","LU1366192091.USD","BK4504","LU1244550221.USD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896665","title":"Zenas Biopharma announces underwritten public offering of convertible senior notes due 2032; terms are set at pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896665?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:04","pubTimestamp":1774555482,"startTime":"0","endTime":"0","summary":"The notes are general, unsecured, senior obligations with interest payable semi-annually.Underwriters have a 30-day option to buy up to an additional 15% of the notes to cover over-allotments.The interest rate, conversion rate and offering price will be set at pricing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL5lSgF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622511896","title":"Zenas Biopharma Inc - Proceeds to Support Obexelimab U.S. Launch, Pipeline Advancement, and General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2622511896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622511896?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:01","pubTimestamp":1774555260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA8TLJWF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622966968","title":"Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2622966968","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622966968?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:01","pubTimestamp":1774555260,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March  26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263386/0/en/Zenas-BioPharma-Announces-Proposed-Concurrent-Public-Offerings-of-Convertible-Senior-Notes-Due-2032-and-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621587507","title":"Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2621587507","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621587507?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:31","pubTimestamp":1774024295,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. ($ZBIO) announced an update on their ongoing clinical study. Zenas BioPharma (ZBIO) is running a phase 3 trial called “A Phas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-progressive-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-progressive-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","LU0742537680.HKD","PGR","LU0354030438.USD","LU1599440770.SGD","LU1983260115.SGD","IE00BKVL7J92.USD","LU1366192091.USD","ZBIO","LU0138981039.USD","BK4588","BK4585","IE0005OL40V9.USD","LU0731783394.SGD","SGXZ23171101.USD","IE00B4JS1V06.HKD","LU0731783048.USD","SG9999003800.SGD","SG9999011175.SGD","IE00BFSS8Q28.SGD","LU1509826696.USD","LU0353189680.USD","LU0354030511.USD","LU0170899867.USD","LU1718418525.SGD","IE00BZ1G4Q59.USD","LU0772969993.USD","LU1035773651.USD","LU0208291251.USD","LU1069347547.HKD","LU1481011671.HKD","LU1430594728.SGD","LU1481011911.USD","LU0070302665.USD","LU2355687059.USD","IE00BN29S564.USD","LU0320765489.SGD","LU2108987350.USD","IE0004445239.USD","IE00B7KXQ091.USD","LU2087625088.SGD","SG9999004303.SGD","IE00BJJMRX11.SGD","IE0004445015.USD","IE00BJJMRY28.SGD","LU0289960550.SGD","IE00B775H168.HKD","BK4107","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420549","title":"Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420549","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420549?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:15","pubTimestamp":1773753347,"startTime":"0","endTime":"0","summary":"In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Zenas BioPharma, Inc., with a price target of $45.00. Nieren...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424332","title":"Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424332?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:07","pubTimestamp":1773749220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 08:07 ET (12:07 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620491426","title":"Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491426","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491426?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:04","pubTimestamp":1773745440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 07:04 ET (11:04 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":-0.0475},{"period":"1month","weight":-0.1934},{"period":"3month","weight":0.2711},{"period":"6month","weight":-0.2313},{"period":"1year","weight":2.0147},{"period":"ytd","weight":-0.4371}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction